Showing results (411-420 of 645) with videos related to

Sort By:
Pageof 65
Thrombosis and Haemostasis|February 28, 1984
Effect of 24 hours of normoglycaemia on tissue-type plasminogen activator plasma levels in insulin-dependent diabetesI Juhan-Vague, P Vague, C Poisson, et al.
Circulation Research|November 1, 1990
Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivoD E Vaughan, P J Declerck, E Van Houtte, et al.
Blood|October 15, 1990
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosisH J Rapold, Z M Wu, T Stassen, et al.
The Journal of Clinical Investigation|January 1, 1994
Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generationP Holvoet, G Perez, H Bernar, et al.
Thrombosis and Haemostasis|March 1, 1996
Characterization of a cDNA encoding murine coagulation factor VIIE Idusogie, E Rosen, J P Geng, et al.
Thrombosis and Haemostasis|October 28, 1987
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activatorJ M Stassen, I Juhan-Vague, M C Alessi, et al.
Thrombosis and Haemostasis|July 6, 1992
Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivoD E Vaughan, P J Declerck, E Van Houtte, et al.
Blood|May 1, 1992
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboonsY Imura, J M Stassen, T Kurokawa, et al.
Thrombosis and Haemostasis|February 12, 1991
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism modelD Collen, H R Lijnen, I Vanlinthout, et al.
Thrombosis and Haemostasis|February 28, 1989
Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis modelD Spriggs, H K Gold, Y Hashimoto, et al.
Pageof 65